Back to Search
Start Over
An Overview of the Efficacy and Safety of Ozanimod for the Treatment of Relapsing Multiple Sclerosis
- Source :
- Drug Design, Development and Therapy
- Publication Year :
- 2021
- Publisher :
- Informa UK Limited, 2021.
-
Abstract
- Multiple sclerosis (MS) is a complex disease of the central nervous system that can cause permanent disability in young adults. A large armamentarium is available for its management and is increasing over time. Ozanimod is an oral drug belonging to the sphingosine-1-phosphate receptor (S1PR) modulator family recently approved in different countries for MS with active disease. It selectively modulates S1PR1 and S1PR5 to prevent autoreactive lymphocytes from entering the central nervous system (CNS), where they can determine inflammation and neurodegeneration. Ozanimod was tested in one Phase II and two Phase III pivotal trials and was shown to be effective and well tolerated. Moreover, further investigations, including comparative trials with other S1P modulators and MS disease-modifying drugs, are needed to better define placement in MS treatment. Furthermore, ozanimod is currently under evaluation for inflammatory bowel diseases, such as ulcerative colitis and Crohn’s disease, in international phase III studies. This article retraces the itinerary leading to the approval of ozanimod for MS treatment and its peculiarities and potentiality inside the S1PR modulator family.
- Subjects :
- Sphingosine 1 Phosphate Receptor Modulators
safety
0301 basic medicine
Ozanimod
Central nervous system
Administration, Oral
Pharmaceutical Science
Inflammation
Review
Disease
Bioinformatics
03 medical and health sciences
chemistry.chemical_compound
Multiple Sclerosis, Relapsing-Remitting
0302 clinical medicine
disease modifying therapy
Drug Discovery
medicine
Animals
Humans
Young adult
Pharmacology
Oxadiazoles
business.industry
Multiple sclerosis
Neurodegeneration
Inflammatory Bowel Diseases
medicine.disease
Ulcerative colitis
030104 developmental biology
medicine.anatomical_structure
chemistry
S1PR modulators
030220 oncology & carcinogenesis
Indans
medicine.symptom
business
brain atrophy
Subjects
Details
- ISSN :
- 11778881
- Volume :
- 15
- Database :
- OpenAIRE
- Journal :
- Drug Design, Development and Therapy
- Accession number :
- edsair.doi.dedup.....86061a19a73348e00086b246121ad401